GRACENCT05636709
National GMA Post-market Clinical Follow-up Study (GRACE)
StatusActive, Not Recruiting
PhaseNot specified
SponsorAdacyte Therapeutics SL
Primary completion (estimated)
At risk: Primary completion moved 12 months later.
Track this trial
Free. We email you which fields changed when ClinicalTrials.gov updates this record.
Record History
All 5 versions: 4 with changes below, 1 re-verified with no change. See every version on ClinicalTrials.gov ↗
Notable Primary and study completion pushed from Jun 30, 2026 to Jun 30, 2027 Show 4 more changesShow less
- Eligibility criteria expanded, about 6 words
- Enrollment closed, study ongoing
- Secondary endpoints: details revised at 9 of 11 entries
- Site details revised at 30 of 30 sites
- Notable Primary and study completion dates pushed to Jun 30, 2026
- Site details revised at 20 of 30 sites
- Minor Study sites: 29 to 30v2
- Study First Submitted
- Notable: the plan changed
- Minor: routine updates
Endpoints
Primary
Proportion of patients achieving steroid-free clinical remission at 6 months after completion of GMA therapy
Timeframe: 6 months
Secondary (11)
Define the regimens used for GMA in actual clinical practice.
Early clinical remission rate
6- and 12-month remission rates completion of GMA therapy
Sustained clinical remission rate
6- and 12-month clinical response rates
Show 6 moreShow less
Rate of patients receiving GMA as maintenance and its efficacy
Rate of patients requiring steroids and mean dose during follow-up
Changes in faecal calprotectin and C-reactive protein (CRP) biomarkers during treatment
Rate of treatment-related adverse events (AEs) and seriousness
Change in patients' quality of life
Number of patients requiring surgery
Arms and interventions
Devices: Adacolumn
Sites
30 sites in 1 country